自贡招聘

The Global External Research and Development (GER&D) function is a virtualised R&D group within Lilly that takes an entrepreneurial approach to helping Lilly deliver medicines across all markets in which it has a presence. This is achieved by seeking commercially viable early and late stage assets, and marketed products for potential in-licensing, partnering and acquisition activities, and also by generating additional value from internal Lilly and externally identified assets via novel financing models in disease areas of high unmet medical need. The group has expertise across the value chain of drug discovery and development, e.g., in new target identification and mechanisms of disease biology, new platform technologies (inc. Chemistry platforms), in vitro and in vivo models of safety and efficacy, through to early phase clinical development, where it has the ability to take compounds through to proof of concept studies via its entrepreneurial Chorus unit. The vast majority of R&D in the Chorus group is delivered virtually via an extensive network of strategic alliances and collaborations with academia, biotechs and CROs.

In order to fulfil its mission, the GER&D function requires to develop and maintain productive interactions with key stakeholders across the whole organisation, including Lilly Research Laboratories (LRL), the individual Business Units (BUs), Corporate Business Development (CBD), Corporate Finance and Investment Banking (CFIB), Lilly Ventures and the Marketing Affiliates in the countries where Lilly has a presence. With respect to the Emerging Markets BU (EMBU), GER&D is responsible for identifying and evaluating new business opportunities which contribute to the organic and inorganic growth strategy and operational objectives of Lilly within these regions. These opportunities can range from, for example, regional development of Lilly or external party molecules via partnering and collaboration deals, through to identification of co-promotion or co-marketing opportunities for Lilly Marketing Companies or equity investments or acquisitions. Additionally, given the increasing levels of innovative science and drug development being undertaken within the Emerging Market regions, opportunities for Lilly to in-license innovative portfolio of assets from regional biotech's and SMEs that can be executed globally, are anticipated to grow significantly in number over the coming years.

Within the Emerging Markets group, a vacancy has recently arisen for a Director role to be based in-market within the Asia Pacific region. The successful candidate will lead a team (to be defined) responsible for identifying and progressing new business opportunities (both inwards and outwards) aligned to the strategy and business objectives of GER&D and EMBU. The position will report into the Region Head, ACEJ/Emerging Markets, GER&D, who is based in Erl Wood, UK.


Job Purpose:

? Lead and co-ordinate activities of GER&D in the Asia Pacific region
? Identify and develop contacts with healthcare innovators in the region to facilitate identification and evaluation of potential opportunities.
? Develop and maintain a long-term relationship with key external organisations involved in healthcare innovation across the region. Track projects of interest and identify optimal models to partner
? Develop and maintain current awareness of in-house R&D activities & priorities for collaboration and in-licensing.
? Develop and maintain a strong communication network with GER&D globally, the China R&D Centre, LRL and with the relevant regional Marketing affiliates and General Managers.
? Analyse and communicate trends in the local/regional markets to advise GER&D and EMBU management on opportunities arising (including opportunities that could have impact in several markets)
? Participate in external activities designed to support and enhance the external awareness of Lilly, and the company profile as a potential partner of choice within Europe and the Middle East.
? Support where appropriate the evolution of the Lilly Fully Integrated Pharmaceutical Network Strategy (FIPNET) regarding a range of shared risk and reward models to support Lilly's drug development needs


Accountabilities:

? Implementation of GER&D Strategy in Asia Pacific :
o Develop strategy and tactics for partnering in Asia Pacific specifically, and the alignment of this with the overall goals and objectives for GERD
o Develop productive relationships and interactions with the Senior Leadership team across GER&D business units and geographies
o Identify opportunities to access novel funding strategies for regional opportunities

? Identification and evaluation of regional opportunities
o Identify and evaluate opportunities from across the region that align with externalisation strategy and priorities of GERD, LRL and the BUs.
o Maintain an awareness of new and planned regional developments (e.g. new sources of innovation funding; strategic initiatives in new areas of healthcare etc) that could deliver new areas of opportunity

? Monitor Progress and Report activities:
o Collate and provide comprehensive view of ongoing initiatives and proposals either active or under development for the Emerging Markets
o Track progress in relevant internal database (Sirius etc.)
o Provide reports on an as-needed basis to monitor activities and progress against objectives

? Transaction support
o In partnership with Corporate Business Development (CBD) develop models for the most appropriate type of agreement to cover each external interaction
o Support the deal flow process to agreement execution and, if relevant, provide post execution support as required

? Facilitate establishing external mechanisms to develop and deliver on Find it, Fund it, and Develop it models in EMs
o Identify and cultivate networks to establish alternate funding mechanisms
o Evaluate and develop R&D capabilities and capacity to support external innovation in EM
o Create opportunities to leverage and expand LRL Chorus capabilities in EMs to support external innovation

? External Relationship Building and Maintenance
o Maintain formal contact channels with current partners (such as regular meetings to discuss current portfolio and potential new opportunities)
o Identify and develop contacts and relationships with new potential partners (Universities, Institutions, Biotechs, Pharmas)
o Develop and maintain high visibility at regional conferences and partnering meetings including invited presentations at key meetings

? Contribute to sharing of best practice
o Attend and contribute to cross-site and cross functional learning opportunities (e.g. cross-BD meetings, Legal/IP workshops)

? People Management
o Develop team to respond to and deliver regional opportunities across Asia Pacific
o Maintain a flexible team-oriented approach to drive performance and deliver high priority projects
o Identify opportunities for team to develop and build their skills and capabilities in order to deliver higher levels of performance


Experience / Knowledge:

? Ideally should have a Ph.D in a relevant scientific discipline or an MD
? Broad knowledge of the pharmaceutical business and drug development process
? 5-10 years experience of working in External R&D/Business Development / Project Management roles across large and small pharma. Experience of working in VC and/or a Public/Private funding organisation would additionally be relevant
? Ability to generate and maintain external networks to support identification and evaluation of new business opportunities
? Track record of identifying, evaluating and initiating strategic collaborations with academia, biotech, CRO and peer pharma companies
? Has significant project and alliance management experience
? Has worked within and/or led cross functional teams (including scientific, clinical, commercial, regulatory) in assessing strategies to enter or leave therapeutic areas
? Experience in managing and driving a portfolio of projects
? Has a thorough understanding of the relevant compliance and governance procedures that relate to the generation and execution of agreements with external parties
? Has the necessary gravitas and experience to represent Lilly across different levels of external partner organisations e.g. from senior scientists, through business development professionals to Board level (CEO, CFO)
? Maintains an awareness of the latest trends in external deal making in the region, particularly as it relates to the interface between academia, industry (biotech and pharma), VC partners and public-private ventures
? Language skills relevant to the Asia Pacific region

美国礼来公司（Eli Lilly and Company）是一家全球性的以研发为基础的医药公司，创立于1876年，总部位于美国印地安那州印第安纳波利斯市。2008年礼来全球销售额突破200亿美元，业务遍及全球 143 个国家和地区，雇佣员工四万多人。

礼来于1918年来到中国，将其第一个海外代表处设在上海。在1993年重新回到中国。已成为业界增长速度最快的制药公司之一。至今，我们在苏州拥有一家独资企业：礼来苏州制药有限公司，30多家办事处，员工已超过1400人。 礼来全球研发中国总部也于2008年10月15日在上海张江高科技园区正式成立。

礼来在中国的许多医药领域居领先地位，如抗感染、中枢神经系统、肿瘤、内分泌等。她的创新药物，不仅挽救病人生命、提高了大众的生活品质，同时也为患者、保健提供者和支付方创造了价值，降低了疾病治疗的成本。

作为全球十大制药企业之一, 礼来始终致力于履行企业社会责任。礼来每年投入巨额资金用于回馈社会。由于礼来在企业社会责任方面的突出贡献，礼来已连续三届荣获《商业周刊》杂志“最慷慨的公司”称号。据《慈善纪事》(Chronicle of Philanthropy)显示，在接受调查的91家美国大型公司中，礼来2006年的捐献数量位居第六。2007年礼来公司慈善捐赠总额约为3.15亿美元，其中包括价值约2.4亿美元的产品捐赠，均用于患者援助计划和国际人道主义事业。2007年公司的捐赠总额大约占公司调整后收入（税前）的6%，再次使礼来成为世界最乐善好施的公司之一。

在中国，礼来也积极推动各项社会公益事业，善尽社会责任，致力成为企业公民的典范。2008年礼来公司在华公益投入总计人民币四千余万元。在南方周末2008中国企业社会责任评选中，礼来中国荣膺“2008世界500强企业慈善公益榜”第3名。

礼来公司有着注重内部培养的用人之道，我们愿意招聘处于职业发展初期的员工加入礼来共同成长并长期服务。当公司出现岗位空缺时，我们能够从内部提拔员工任职或转岗。在礼来中国，我们的管理层有95%来自内部提拔。我们还创建了一种注重员工培训与发展的文化和系统。因此，在业界，我们有“礼来大学”之美誉。我们的培训系统，在职辅导系统，和接班人计划尤其为人们所广为称道。 礼来有着注重绩效和行为并重的文化传统，同时为员工提供全面的薪酬福利保障。 我们以最高道德标准管理我们的业务并在日常工作中要求我们所有的员工。我们相信符合最高道德标准的行为将最终使我们的公司和员工受益。

礼来对中国市场有着中长期的发展战略，我们对这个市场雄心勃勃。从2006开始， 礼来公司启动彩虹计划在内分泌， 抗肿瘤及中枢神经领域进行扩招， 我们的员工队伍已增加了40％，达到了1100多人， 为公司的发展做出来巨大的贡献。从2009年到2013年， 礼来将会进一步加大对中国的投资力度， 礼来中国将进行前所未有的扩张计划。

如果你一直想加入这家有着良好声誉的公司， 现在， 机会之门正在敞开！我们寻求年轻的你， 优秀的你， 自信的你加入我们， 和礼来一起共同成长。无论你是经验丰富的专业人士， 还是胸怀壮志的应届毕业生，相信礼来的内部提拔机制和在职培训系统能够给你的职业和人生带来彩虹般的精彩。 如果你够自信, 够优秀,充满对成功的渴望, 来吧，加入我们， 礼来将助你成就梦想！